3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
3
Recurrence
2
Neoplasms
2
Hypersensitivity
2
Uterine Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Adenocarcinoma
1
Interventions
Paclitaxel
7
Pemetrexed
3
Cisplatin
3
Carboplatin
3
pembrolizumab
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Radiotherapy
2
Nivolumab
2
FANG vaccine
2
Docetaxel
2
CP protocol
2
Brachytherapy
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
niraparib
1
larotrectinib
1
ipatasertib
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT03951415
2021-04-01
DOMEC
Leiden University Medical Center
Phase 2
Unknown
55 enrolled